Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - buserelin - implant - 6.3 milligram

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - buserelin acetate -

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited - buserelin acetate - implant - 9.9 milligram

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - buserelin acetate 1 mg/ml - nasal spray solution - 1 mg/ml - active: buserelin acetate 1 mg/ml

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - buserelin acetate 6.6mg equivalent to 6.3 mg of buserelin - subcutaneous implant - 6.3 mg - active: buserelin acetate 6.6mg equivalent to 6.3 mg of buserelin excipient: polyglactin

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - buserelin acetate 9.9mg equivalent to 9.45 mg of buserelin - subcutaneous implant - 9.45 mg - active: buserelin acetate 9.9mg equivalent to 9.45 mg of buserelin excipient: polyglactin

Israel - English - Ministry of Health

sanofi - aventis israel ltd - buserelin acetate 6.6 mg - rods for implant - buserelin - treatment of advanced hormone - dependent prostatic carcinoma.

Israel - English - Ministry of Health

sanofi - aventis israel ltd - buserelin as acetate 0.1 mg/actuations - solution - buserelin - treatment of advanced hormone dependent prostatic carcinoma. endometriosis. use in ivf. precocious puberty. leyomyoma uteri.

Bahrain - English - الهيئة الوطنية لتنظيم المهن والخدمات الصحية، مملكة البحرين

yousif mahmood hussain pharmacy - buserelin acetate - nasal spray - 0.1

Bahrain - English - الهيئة الوطنية لتنظيم المهن والخدمات الصحية، مملكة البحرين

yousif mahmood hussain pharmacy - buserelin - injection